Female Orgasmic Disorder involves a primary difficulty reaching orgasm despite adequate stimulation and arousal; Substance/Medication-Induced Sexual Dysfunction is diagnosed when a clinically significant sexual dysfunction, including difficulty reaching orgasm, is judged to be the direct physiological consequence of a substance or medication, most commonly SSRIs and other antidepressants.
Substance/Medication-Induced Sexual Dysfunction typically has a clear temporal relationship to starting or increasing the dose of a causative agent; Female Orgasmic Disorder, when primary, is not tied to a specific medication change and may be lifelong or have a more gradual acquired onset.
Both can be persistent as long as the relevant condition or exposure continues; medication-induced orgasmic difficulty often improves after the causative agent is discontinued, adjusted, or switched, in contrast to a primary Female Orgasmic Disorder that would not be expected to resolve with medication changes alone.
Female Orgasmic Disorder is associated with variability in orgasmic response across different types of stimulation; Substance/Medication-Induced Sexual Dysfunction's features track the specific causative agent, with SSRIs being a particularly well-documented cause of delayed or absent orgasm in both women and men.
Both require clinically significant distress for diagnosis; recognizing a medication-induced contribution is clinically actionable, since a dose adjustment or medication switch may resolve symptoms in a way that treating a primary orgasmic disorder would not.
Female Orgasmic Disorder is not diagnosed when the orgasmic difficulty is better explained by the direct physiological effects of a substance or medication, which should always be considered and ruled out first, particularly given how common SSRI-related orgasmic difficulty is.
The key differential question is temporal and causal: did the orgasmic difficulty predate any relevant medication or substance exposure (favoring primary Female Orgasmic Disorder), or did it begin or clearly worsen after starting or increasing a known culprit medication, particularly an SSRI (favoring Substance/Medication-Induced Sexual Dysfunction)?
Because SSRI-related orgasmic difficulty is extremely common and often under-recognized, it can be misattributed to a primary Female Orgasmic Disorder if the medication list isn't carefully reviewed as part of the initial assessment.
A woman who developed new difficulty reaching orgasm shortly after starting an SSRI for depression, with no such difficulty before starting the medication, points toward Substance/Medication-Induced Sexual Dysfunction; a woman with a lifelong pattern of difficulty reaching orgasm, unrelated to any medication, points toward Female Orgasmic Disorder.
| Feature | Female Orgasmic Disorder | Substance/Medication-Induced Sexual Dysfunction |
|---|---|---|
| Temporal relationship | Female Orgasmic Disorder: not tied to a specific medication change | Substance/Medication-Induced: clear onset/worsening after starting/increasing an agent |
| Response to medication adjustment | Not expected to resolve with medication changes alone | Often improves after stopping/switching the causative agent |
| Common causative agent | Not applicable | SSRIs and other antidepressants are well-documented causes |
Marked delay in, marked infrequency of, or absence of orgasm, or markedly reduced intensity of orgasmic sensation, on almost all or all occasions of sexual activity, for a minimum duration of approximately 6 months, causing clinically significant distress.
A clinically significant disturbance in sexual function that developed during or soon after substance intoxication, withdrawal, or exposure to a medication capable of producing sexual dysfunction, where the substance/medication is judged etiologically related to the disturbance.